ASCO2022 | 不能错过的6篇肺癌POSTER 近日举行的2022 ASCO大会公布了多项肺癌领域的摘要,本文讲聚焦6篇肺癌领域的高光poster,为您献上精华和点评。 摘要编号 9021 晚期非小细胞肺癌患者PD-L1抑制剂获得性耐药的基因组相关性1 研究设计: 晚期非小细胞肺癌(NSCLC)...
这些初步结果表明,CT041对先前接受过治疗的晚期G/GEJ腺癌患者具有可管理的安全耐受性,并具有良好的疗效。该研究正在进行中,正在进一步研究CT041不确定期Il期。表1:。人口统计学和基线特征稳定2。AES人口统计学和基线特征总结SN(2%)中位年龄(范围),4.5岁(23-71岁)(100%66(42.9%)とGade3ECOG PS=1,n(%)12(8...
a clinical-stage company with anin situvaccination technology platform, announces that an abstract relating to LTX-315 in combination with Adoptive Cell Therapy (ACT) has been selected for presentation at a Poster Session during...
编者按:2022年美国临床肿瘤学会年会(2022 ASCO)将于当地时间6月3～7日在芝加哥以线上、线下会议的形式举行。美国临床肿瘤学会(ASCO)年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议,汇集了众多世界一流的肿瘤学专家。本文汇总了本届ASCO大会乳腺癌领域的中国好声音(排名不分先后,未包括e-poster),如...
(ASCO) 2022 Annual Meeting. The poster showcases the study design for the company’s first-in-human Phase 1/2 trial of AU-007 that is currently enrolling patients in Australia. AU-007 is a human monoclonal antibody computationally designed by Biolojic Design, with a highly differentiated ...